Their head of strategy, Luke Miels leaves for GSK. CEO then departs for TEVA. Looks like they were possibly getting nervous about upcoming trial results. Looks like AZN is off the list of potential buyers for AMRN now with this news. Many on here have speculated with them as possible buyers for AMRN. AZN now likely to be on the selling block.
Market Data 
Markets 
AI
